KCL-286
KCL-286 (C286), is a potent, orally bioavailable retinoic acid receptor beta (RARβ) agonist (EC50 = 1.9nM) with good selectivity over the RARα, and RARγ receptors.
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
KCL-286 (C286), is a potent, orally bioavailable retinoic acid receptor beta (RARβ) agonist (EC50 = 1.9nM) with good selectivity over the RARα, and RARγ receptors. This molecule increases neurite outgrowth in vitro and stimulates sensory axon regrowth in vivo in a rodent model of crush and avulsion injury, and is being evaluated for the treatment of nerve injury.
It has antiinflammatory and neuroregeneration-promoting effects in humans and is now in clinical trials for the treatment of Alzheimer's disease and spinal cord injury following positive results in animal studies.
Text derived from https://en.wikipedia.org/w/index.php?oldid=1366664140 under CC BY-SA 4.0; modifications have been made.